Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicago Inc MDCGF



GREY:MDCGF - Post by User

Comment by Delmicon Sep 15, 2010 10:15am
276 Views
Post# 17450302

RE: RE: Attention Attention

RE: RE: Attention AttentionTechnically, this is not impossible. A vaccine must elicit a complete immune response (this process needs antigen presentation to antibody-producing cells). This is done through close contact between dendritic cells or macrophages and B lymphocytes. Dendritic cells and macrophages are not responsible for immune memory, B and T lymphocytes are. Only a strong and sustained immune response will trigger a conversion of active B and T cells to memory cells.

Bacteria antigens are not recognized by the same receptors which will trigger an immune response leading to the generation of memory cells (long-term immunity). However, through cell surface antigen modification it may be possible to produce a vaccine which will protect form bacteria infections.

I believe Merck is currently developing a vaccine for Staph Aureus (phase 2).

Let's get MDG show first what they can do with viruses.

Delmic

<< Previous
Bullboard Posts
Next >>